- Clinigen Signs Exclusive Agreement with Xeris Pharmaceuticals to Supply and Distribute Gvoke™ Outside the US.
"It is especially important during this global health crisis that people with diabetes, who the CDC and others have identified as an at-risk population, have access to medicines like Gvoke, which can enable them to self-treat and avoid going to a busy hospital or medical center to receive care."
- Xeris Pharmaceuticals Announces Gvoke HypoPen™ – the First Autoinjector for Severe Hypoglycemia – Now Available
“Gvoke HypoPen the First Autoinjector for Severe Hypoglycemia now available by prescription in the U.S. for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above. Gvoke HypoPen is the first ready-to-use glucagon in a premixed autoinjector, with no visible needle.”
https://www.businesswire.com/news/home/20200701005285/en/(Photo:
- US DEPARTMENT OF VETERANS AFFAIRS $4.1million contract award notice opportunity.
https://beta.sam.gov/opp/acb59c12ce004ebf832c456d8c10d283/view
- Financial Obligation Form 8-K
“The Company also prepaid all of its approximately $4.2 million in borrowings under the PPP Loan.”
- “Strong Buy” Analyst Consensus
- Price Target of $12.50
https://www.tipranks.com/stocks/xers/price-target
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.
About Xeris Pharmaceuticals, Inc
Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world. With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke™. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion.
Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com
Sources:
https://www.businesswire.com/news/home/20200701005285/en/(Photo:
https://www.worldpharmatoday.com/news/clinigen-signs-exclusive-agreement...
https://beta.sam.gov/opp/acb59c12ce004ebf832c456d8c10d283/view
https://www.marketscreener.com/XERIS-PHARMACEUTICALS-IN-44336192/news/XE...
https://www.tipranks.com/stocks/xers/price-target
https://xerispharma.gcs-web.com/news-releases/news-release-details/xeris...